Syngene International, a global contract research, development, and manufacturing organization (CRDMO), has announced the extension of its long-standing strategic collaboration with Bristol Myers Squibb (BMS) through 2035. The expanded agreement significantly broadens the scope of integrated services across the entire drug development lifecycle, enabling a seamless transition from early research to commercialization.
Expanded Scope Covers End-to-End Drug Development
Under the renewed collaboration, Syngene will deliver integrated capabilities across discovery, development, and manufacturing. These include chemistry, biology, drug metabolism and pharmacokinetics, translational sciences, pharmaceutical development, manufacturing, clinical trials, as well as data and information technology services. As a result, the partnership will allow Bristol Myers Squibb to accelerate the progression of drug candidates from laboratory research to commercial production.
Partnership Enters Next Phase of Growth
The extension marks the next phase of growth in a collaboration that has already spanned more than two decades. Importantly, it reinforces Syngene’s role as a strategic partner capable of providing end-to-end scientific and manufacturing solutions at scale.
Leadership Highlights Long-Term Strategic Value
Peter Bains, Managing Director and CEO of Syngene International, emphasised the long-standing foundation of the partnership. “Our collaboration with Bristol Myers Squibb, which now spans more than 25 years, is built on scientific excellence, operational reliability, and a shared commitment to advancing innovative therapies. Extending this partnership through 2035 allows us to jointly plan future capabilities and infrastructure with a long-term horizon,” Bains said.
He added that this forward-looking approach strengthens strategic value for both companies. It also positions Syngene to support BMS’s next wave of discovery, development, and manufacturing programmes, with the potential to improve patient outcomes globally.
BMS Reaffirms Patient-Centric Focus
Payal Sheth, Senior Vice President, Therapeutic Discovery Sciences at Bristol Myers Squibb, highlighted the importance of the collaboration in advancing patient-focused innovation. “Everything we do at Bristol Myers Squibb begins with patients. Our long-standing partnership with Syngene has played a key role in advancing our scientific ambitions. This expanded collaboration reflects our commitment to integrating research, development, and manufacturing capabilities to accelerate the delivery of transformative medicines,” she said.
Collaboration Built on a 25-Year Legacy
The Syngene–Bristol Myers Squibb collaboration began in 1998. It led to the establishment of the Biocon Bristol Myers Squibb Research and Development Center (BBRC), Syngene’s first dedicated R&D centre, which was fully commissioned in 2009.
Over the years, BBRC has evolved into a major strategic R&D hub for Bristol Myers Squibb. The centre supports integrated capabilities across target identification and lead discovery and optimisation. It also covers pharmaceutical development, molecular and cell biology, protein sciences, assay biology, and clinical biomarkers.
BBRC Drives Global Research Programmes
As reported by prnewswire.com, BBRC employs around 700 Syngene scientists. They work as an extension of Bristol Myers Squibb’s global research organisation. The centre contributes to discovery, preclinical development, and patent filings. Its work spans key therapeutic areas, including cardiovascular diseases, fibrosis, immunology, and oncology.
